Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 9/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | JAK1 | P23458 | 6/20 | 0.48 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123730 | 0.90 | TTK (0.45) | TTKMCHR1JAK2JAK1MAPKAPK5 | |
| SCHEMBL22122900 | 0.85 | TTK (0.54) | TTKMAPKAPK5AURKA | |
| SCHEMBL22125448 | 0.83 | TTK (0.51) | TTKMCHR1JAK2MAPKAPK5AURKA | |
| SCHEMBL22125450 | 0.83 | TTK (0.52) | TTKMAPKAPK5 | |
| SCHEMBL22122895 | 0.81 | TTK (0.52) | TTKMAPKAPK5AURKA | |
| SCHEMBL24911179 | 0.81 | TTK (0.47) | TTKJAK2JAK1MAPKAPK5AURKA | |
| SCHEMBL22122974 | 0.81 | TTK (0.49) | TTKJAK2MAPKAPK5AURKA | |
| SCHEMBL22122916 | 0.80 | TTK (0.49) | TTKMAPKAPK5AURKA | |
| SCHEMBL24910455 | 0.80 | TTK (0.48) | TTKJAK2JAK1MAPKAPK5AURKA | |
| SCHEMBL22123693 | 0.79 | TTK (0.56) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898629-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | TTK 4519/4885MCHR1 3589/4885JAK2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.